Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | Avaxia Biologics - Gut-targeted antibody |
Description | About Us Overview Contact Technology Overview Platform Publications Programs Avaximab™-TNF Sildenafil Citrate Research Partners Partners Investors Investo |
Keywords | N/A |
WebSite | avaxiabiologics.com |
Host IP | 198.252.102.248 |
Location | United States |
Site | Rank |
US$1,827,163
Last updated: 2023-05-15 01:12:58
avaxiabiologics.com has Semrush global rank of 5,792,753. avaxiabiologics.com has an estimated worth of US$ 1,827,163, based on its estimated Ads revenue. avaxiabiologics.com receives approximately 210,827 unique visitors each day. Its web server is located in United States, with IP address 198.252.102.248. According to SiteAdvisor, avaxiabiologics.com is safe to visit. |
Purchase/Sale Value | US$1,827,163 |
Daily Ads Revenue | US$1,687 |
Monthly Ads Revenue | US$50,599 |
Yearly Ads Revenue | US$607,181 |
Daily Unique Visitors | 14,056 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
avaxiabiologics.com. | A | 14400 | IP: 198.252.102.248 |
avaxiabiologics.com. | NS | 86400 | NS Record: ns1.hawkhost.com. |
avaxiabiologics.com. | NS | 86400 | NS Record: ns2.hawkhost.com. |
avaxiabiologics.com. | MX | 14400 | MX Record: 0 avaxiabiologics.com. |
avaxiabiologics.com. | TXT | 14400 | TXT Record: v=spf1 +a +mx +ip4:198.252.105.23 +ip4:198.252.102.248 +ip4:72.29.127.24 +include:_spf.arandomserver.com ~all |
About Us Overview Contact Technology Overview Platform Publications Programs Avaximab™-TNF Sildenafil Citrate Research Partners Partners Investors Investors Media Press Releases In The News Avaxia leads the field of gut-targeted antibody therapeutics Overview Circle33 has acquired all the patents, technology and assets of Avaxia Biologics for the development of orally administered, gut-targeted antibody therapeutics. - Product concept demonstrated in Phase 1b clinical trial of AVX-470 in UC. AVX-470 - a bovine polyclonal milk-derived anti-TNF antibody Established GI-stability for delivery of specific milk-derived bovine antibodies Penetration into local tissue (needed for inflammatory targets) Minimal systemic exposure and low immunogenicity Anti-TNF biological activity and proof of mechanism observed in preclinical models and in IBD patients - Technology to create orally administered, GI-stable recombinant monoclonal antibodies: Avaximabs™. Investment with online lender LendUp of |
HTTP/1.1 200 OK Connection: Keep-Alive Keep-Alive: timeout=5, max=100 x-powered-by: PHP/5.6.40 content-type: text/html; charset=windows-1250 content-length: 9185 date: Fri, 24 Dec 2021 08:57:14 GMT server: LiteSpeed |
Domain Name: AVAXIABIOLOGICS.COM Registry Domain ID: 251777477_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2021-10-26T09:09:36Z Creation Date: 2005-11-09T22:32:59Z Registry Expiry Date: 2022-11-09T22:32:59Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS1.HAWKHOST.COM Name Server: NS2.HAWKHOST.COM DNSSEC: unsigned >>> Last update of whois database: 2021-12-20T08:15:22Z <<< |